These data will inform further development of STING agonists in cancer immunotherapy and help address open questions surrounding optimal cell type targeting and systemic feedback regulation of STING, selection of patients with cancer for therapeutic agonism, as well as the optimal route of administration. Here, STING1 is linked to cancer.